Search
User Profile
Change
Select your user profile

Roche NT-proBNP

Elecsys® NT-proBNP
Despite the treatments available, hospitalization and mortality rates remain high.1

Despite the treatments available for heart failure, hospitalization and mortality rates remain high. Optimized heart failure management is the key to improved patient outcomes and quality of life.1,3,4   With over 20 years of clinical evidence, Roche NT-proBNP provides support throughout the continuum of care in heart failure.5-6

 

Analytical Advantage

NT-proBNP has analytical advantages over BNP

View Full Table
close

NT-proBNP has analytical advantages over BNP

Characteristics BNP NT-proBNP 7 NT-proBNP Advantages 7 
Half-life 20 minutes

 

60-120 minutes

 

 Less prone to intra-day variability8
Stability Varies 4-24 hours at room temperature

 

Up to 3 days at room temperature

 

 Greater stability enables lab flexibility for outreach and add-on testing

Standardization

BNP assays are not standardized across manufacturers

NT-proBNP assays, unlike BNP,  are standardized across manufacturers. In the Emergency Department and inpatient and outpatient settings, consistent results allow for more confidence in heart failure management.

Clinical Excellence

NT-proBNP delivers confidence when managing patients across the heart failure spectrum.

Do you have any questions?
Contact us

References

  1. World Heart Failure Alliance. White Paper: Heart failure, preventing disease and death worldwide. Web: https://www.escardio.org/static_file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf. Accessed May 2023.
  2. Piotr Ponikowski-Heart Failure- Preventing Disease and Deth Worldwide\World Heart Failure Alliance.
  3. Cowie, M.R. et al. (2013) Improving care for patients are acute heart failure. Retrieved from: http://www.oxfordhealthpolicyforum.org/reports/acute-heart-failure/improving-care-for-patients-with-acute-heart-failure. Accessed May 2023.
  4. Krumholz HM, et al. (2009). Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes.;2(5):407-413
  5. Francis et al. (2016). J Am Coll CArdil. 67(3), 330 – 337
  6. PubMed Central®: search results for “Roche NT-proBNP heart failure”. Accessed on January 2018
  7. Reference: Elecsys NT-proBNP Package Insert
  8. Emdin M. Clin Chem. 2007;53:71289-71297.